Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amylx Pharmaceuticals Inc (AMLX) vs iShares 7-10 Year Treasury Bond ETF (IEF) Price & Performance

Amylx Pharmaceuticals IncTrade
iShares 7-10 Year Treasury Bond ETFTrade

Price performance (Past 24H)

Key statistics

Amylx Pharmaceuticals Inc vs iShares 7-10 Year Treasury Bond ETF — how do they compare? Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.53B), while iShares 7-10 Year Treasury Bond ETF trades at $92.9. The key difference: Amylx Pharmaceuticals Inc is trading nearer its 52-week high, iShares 7-10 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.

AMLXIEF
Market Cap
$2.53B
Sector
Health
52-Week High
$24.19$97.99
52-Week Low
$7.82$92.76
Enterprise Value
$2.28B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amylx Pharmaceuticals Inc

AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.

Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.

iShares 7-10 Year Treasury Bond ETF

IEF (iShares 7-10 Year Treasury Bond ETF) trades at $93.17 with minimal daily movement (+0.24%). Technical indicators show a neutral to bearish bias with moving averages signaling caution. The ETF maintains consistent dividend distributions, with recent payments of $0.31-$0.32 per share. Market focus remains on Treasury yield movements influenced by inflation data and Middle East tensions affecting oil prices.

Outlook remains tied to interest rate expectations and inflation trends. Recent institutional accumulation by Bank of America and Ferguson Shapiro provides support, but rising Treasury yields pose headwinds. Key risks include Federal Reserve policy shifts and geopolitical volatility impacting bond markets.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amylx Pharmaceuticals Inc

Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.

Read more on AMLX

About iShares 7-10 Year Treasury Bond ETF

The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.

Read more on IEF